Skip to main content

Table 3 Association of history coronary artery disease or heart failure to various outcomes of interest among COVID-19 patients in the Philippine CORONA Study

From: Outcomes of patients with COVID-19 and coronary artery disease and heart failure: findings from the Philippine CORONA study

Outcomes

Estimatea

95% CI

p value

Adjusted Estimateb

95% CI

p value

Dichotomous outcomes

      

Severe/critical COVID-19c

2.89

2.41, 3.47

< 0.001

   

Full/partial improvement of

neurologic deficit/s

0.44

0.29, 0.67

< 0.001

0.94

0.59, 1.51

0.799

All-cause mortality

2.43

1.99, 2.95

< 0.001

1.06

0.85, 1.33

0.577

Death from cardiac cause

2.61

1.79, 3.81

< 0.001

2.22

1.49, 3.32

< 0.001

Respiratory failure

3.06

2.52, 3.71

< 0.001

1.21

0.97, 1.51

0.084

Prolonged duration of ventilator

dependence

0.48

0.30, 0.77

0.002

0.99

0.60 1.62

0.957

Prolonged length of ICU stay

1.39

0.89, 2.17

0.150

1.58

1.00, 2.52

0.052

Prolonged length of hospital

stay

1.43

1.19, 1.70

< 0.001

1.16

0.96, 1.40

0.124

Time-to-event outcomes

      

All-cause mortality

1.43

1.21, 1.69

< 0.001

0.98

0.83, 1.17

0.846

Death from cardiac cause

3.02

2.18, 4.18

< 0.001

1.91

1.34, 2.71

< 0.001

Respiratory failure

2.59

2.20, 3.03

< 0.001

1.07

0.90, 1.26

0.437

  1. aOdds ratio for dichotomous outcomes, and hazard ratio for time-to-event outcomes
  2. bAdjusted for age, sex, smoking history, comorbidities with hypertension, diabetes mellitus, chronic obstructive pulmonary disease, bronchial asthma, kidney disease, and stroke, and, receiving tocilizumab, steroid, anti-platelet, remdesivir, and covalescent plasma therapy.
  3. COVID – Coronavirus disease; ICU – intensive care unit; CI – confidence interval